Clinical trials: Venothromboembolism, active
Venothromboembolism
AI-driven Clinical Decision Support to Reduce Hospital-Acquired Venous Thromboembolism: Study Protocol for the VTE-AI Randomized Trial.
Hospital-acquired blood clots (HA-VTE) are the leading cause of death in hospitalized patients in the US. Each year, about 900,000 people get blood clots, costing between $7 and $10 billion in medical expenses.
- Trial name
- VTE-AI RCT (NCT06939803)
- Testing
- Risk model-driven CDS
- Where
- United States
- Volunteers
- 2,236 people
- Sponsor
- Vanderbilt University Medical Center